Status:
COMPLETED
Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?
Lead Sponsor:
Sapporo Medical University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
35-80 years
Brief Summary
In this study, the investigators hypothesized that significant proportion of patients with coronary artery disease (CAD) has reduced capacity of glucagon-like peptide-1 (GLP-1) secretion, which is det...
Detailed Description
Recently, the investigators found that a significant proportion of subjects in a general population shows attenuated secretion of active GLP-1 in response to oral glucose loading and that the insuffic...
Eligibility Criteria
Inclusion
- Non-diabetic patients (HbA1c \<6.5%) with suspected or diagnosed CAD at ages of 35-80 years who are hospitalized for coronary angiogram will included in this study. - No change in medications (if any) for dyslipidemia within 3 month prior to admission is also a criterion for inclusion.
Exclusion
- Diabetic patients whose HbA1c is higher than 6.5% or who have received insulin or hypoglycemic agents and those who need immediate pharmacological treatments after admission will be excluded.
- Patients with history of PCI also will be excluded.
Key Trial Info
Start Date :
February 27 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 29 2020
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT02280837
Start Date
February 27 2015
End Date
December 29 2020
Last Update
February 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sapporo Medical University, School of Medicine
Sapporo, Hokkaido, Japan, 0608556